Hostname: page-component-7479d7b7d-jwnkl Total loading time: 0 Render date: 2024-07-13T10:34:45.414Z Has data issue: false hasContentIssue false

Serotonin syndrome due to association of venlafaxine, maprotiline and reboxetine

Published online by Cambridge University Press:  16 April 2020

José-Manuel Bertolín-Guillén
Affiliation:
Hospital Psychiatric Unit, Service of Psychiatry, Consorcio Hospital General Universitario de Valencia, Avda. Tres Cruces s/n, 46014 Valencia, Spain
Benjamín Climent-Díaz
Affiliation:
Toxicology Unit, Service of Internal Medicine, Consorcio Hospital General Universitario de Valencia, Avda. Tres Cruces s/n, 46014Valencia, Spain
Arancha Navarré-Gimeno
Affiliation:
Service of Neurology, Consorcio Hospital General Universitario de Valencia, Avda. Tres Cruces s/n, 46014Valencia, Spain

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Letter to the editor
Copyright
Copyright © European Psychiatric Association 2004

References

Bhatara, V.S, Magnus, R.D, Paul, K.L, Preskorn, S.HSerotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Ann Pharmacother 1998; 32; 432-6.CrossRefGoogle ScholarPubMed
Diamond, S, Pepper, B.J, Diamond, M.L, Freitag, F.G, Urban, G.J, Erdemoglu, A.KSerotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports. Neurology 1998; 5; 274-6.CrossRefGoogle Scholar
Pan, J.J, Shen, W.WSerotonin syndrome induced by low-dose venlafaxine. Ann Pharmacother 2003; 37; 209-11.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.